case_images: PMC4671814_01
case_images: Contrast-enhanced CT of the chest demonstrating the response to treatment of unresectable metastatic colorectal carcinoma.. Notes: (A) Mediastinal conglomerate mass of enlarged lymph nodes (arrow). (B) Conglomerate masses (arrow) upon initiation of dabrafenib/trametinib/oxaliplatin therapy. (C) Interval decrease in size of mediastinal nodes (arrow) after 1 month of therapy. (D) Interval resolution of mediastinal lymph nodes (arrow) after 3 months of therapy. (E) Absent mediastinal lymphadenopathy (arrow) at 6 months after therapy.
case_images: ott-8-3561Fig1.jpg
case_images: PMC4671814_01_ott-8-3561Fig1.jpg
case_images: f1-ott-8-3561
case_images: While hospitalized, the patient underwent restaging scans, which demonstrated new lymph node lesions in the anterior mediastinum as well as multiple new bilobar liver lesions consistent with progressive disease (Figures 1 and 2).
case_images: Contrast-enhanced CT of the abdomen demonstrating resolution of hepatic lesions in an unresectable metastatic colorectal carcinoma.. Notes: (A) Hepatic lesions (arrows) prior to initiation of dabrafenib/trametinib/oxaliplatin therapy. (B) Hepatic lesions (arrows) upon initiation of therapy. (C) Interval decrease in size of liver lesions (arrows) after 1 month of therapy. (D) Interval resolution of liver lesions (arrows) after 3 months of therapy. (E) Absent liver lesions (arrows) at 6 months after therapy.
case_images: ott-8-3561Fig2.jpg
case_images: PMC4671814_01_ott-8-3561Fig2.jpg
case_images: f2-ott-8-3561
case_images: While hospitalized, the patient underwent restaging scans, which demonstrated new lymph node lesions in the anterior mediastinum as well as multiple new bilobar liver lesions consistent with progressive disease (Figures 1 and 2).